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Objective. To evaluate the risk of serious infections in rheumatoid arthritis (RA) offspring exposed to tumor necrosis factor inhibitors (TNFi) in the gestational period compared to unexposed RA offspring, as well as to children from the general population.
Methods. We used US claim data (2011-2015) to identify 2,989 offspring born to women who have RA and a randomly selected group of 14,596 control children, matched ≥4:1 for maternal age, year of delivery, and state of residence. We defined TNFi exposure based on ≥1 filled prescription during pregnancy. We ascertained serious infections based on ≥1 hospitalization, with infection as a primary diagnosis, at ≤12 months of life. We performed multivariable analyses, adjusting for maternal demographics, comorbidities, pregnancy complications, and drugs.
Results. Among RA offspring, 380 (12.7%) were exposed to TNFi during pregnancy. The percentage of serious infections in RA offspring with no TNFi exposure (2.0%; 95% confidence interval [95% CI] 1.5, 2.6) was similar to that in non-RA offspring (1.9%; 95% CI 1.9, 2.2), while the percentage of serious infections in RA offspring with TNFi exposure was 3.2% (95% CI 1.5, 5.6). In multivariable analyses, we were unable to establish an increased risk of serious infections in RA offspring exposed to TNFi versus both non-RA offspring (odds ratio [OR] 1.7, 95% CI 0.8, 3.7) and RA offspring unexposed to TNFi (OR 1.4, 95% CI 0.7, 2.8).
Conclusion. We did not demonstrate a marked excess risk for serious infections in RA offspring exposed to TNFi during pregnancy versus unexposed RA offspring or general population controls.
In North America, infections are the leading cause of mortality in children age <5 years, accounting for >30% of deaths (1) . Tumor necrosis factor inhibitors (TNFi) are important drugs in the treatment of rheumatoid arthritis (RA), being used in one-third of patients (2) . Since animal studies did not show fetal risk, TNFi have been commonly and increasingly used during pregnancy, now prescribed in 20% of RA pregnancies, representing a 3-fold increase over the past 10 years (2). Despite existing concerns that these potent drugs may cause immunosuppression, there are limited data on the risk of serious infection in exposed offspring.
During pregnancy, there is active transplacental transport of maternal circulating immunoglobulins (IgG) through their Fc portion (3) . TNFi are all monoclonal IgG with an Fc part, except for etanercept and certolizumab, which are, respectively, a fusion protein with an Fc portion and a PEGylated Fab fragment without an Fc component (4, 5) . Thus, most TNFi are actively transported across the placenta, with some reaching higher fetal than maternal blood levels. For instance, infliximab and adalimumab have the highest transplacental transfer (reaching cord blood median levels at, respectively, 160% and 150% of maternal blood levels), while etanercept and certolizumab display the lowest passage (cord blood median levels at, respectively, 4-7% and <0.25% of maternal blood levels) (4) (5) (6) (7) (8) .
As fetuses could be exposed to therapeutic (and potentially supratherapeutic) TNFi doses, there are concerns that they could cause immunosuppression in the offspring. These concerns were initially raised following the case report in 2010 of a mother with Crohn's disease receiving infliximab throughout pregnancy (9) . After an uncomplicated delivery, her healthy infant received a BCG vaccine at 3 months of age and died of disseminated tuberculosis (TB). Due to the potential for immunosuppression in exposed offspring and because of the TNFi differential half-life and transplacental transfer, the European League Against Rheumatism recommends discontinuing infliximab and adalimumab before 20 weeks of gestation and etanercept before 31-32 weeks to minimize the risk of infections in offspring, while they state that certolizumab can be continued throughout pregnancy (10) . The British Society of Rheumatology guidelines for use of drugs during pregnancy also state that certolizumab is compatible with all 3 trimesters of pregnancy, but differ slightly in recommending that infliximab be discontinued before 16 weeks, and that etanercept and adalimumab be stopped before the end of the second trimester (8) .
Until now, there has been no reported study on the risk of infection in RA offspring exposed in utero to TNFi versus unexposed offspring. Therefore, we aimed to evaluate serious infections in RA offspring exposed to TNFi in the preconception and/or gestational period compared to unexposed RA offspring, as well as to children from the general population.
PATIENTS AND METHODS
Data source and study population. We assembled the Pregnancies in RA Mothers and Outcomes in Offspring in the United States (PAROUS) cohort, a population-based cohort of children born to women who have RA and a matched control group of children born to unaffected mothers, using MarketScan commercial databases (January 1, 2011 to December 30, 2015). The MarketScan commercial database is a large prospective US database of >230 million subjects with employer-provided health insurance (11) . It contains data on hospitalizations, outpatient visits, and drug prescription claims.
To create the PAROUS cohort, we identified women ages 15-45 years as RA subjects (using the International Classification of Diseases, Ninth and/or Tenth Revisions [ICD-9/10] code 714/M05) if they had any of the following: 1) ≥1 hospitalization with a diagnosis of RA at or prior to delivery, or 2) ≥2 physician visits with a diagnosis of RA, the first occurring at any time prior to the delivery and the second at any point during the study period. This RA case definition demonstrated a high sensitivity (83%) and excellent specificity (99%) when using physician diagnosis as a reference (12) . A group of women without RA was randomly selected and matched ≥4:1 for age, year of delivery, and geographic location (i.e., state, division, and region) of the primary beneficiary's residence. Only women continuously enrolled within MarketScan with medical and pharmacy coverage for ≥12 months prior to delivery were included in PAROUS. We then identified the children born live to RA and unexposed women, linking mothers with their infants deterministically using family identifiers and delivery dates corresponding to birth year. Children were followed up from birth until 12 months of age, first event of interest (i.e., serious infection), end of commercial insurance eligibility, death, or end of study period (December 30, 2015), whichever came first.
Delivery was defined using any inpatient hospital admission record including a pregnancy-related diagnosis or procedure code for vaginal or caesarean delivery identified by the relevant ICD-9/10 codes and/or procedure codes (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40536/abstract). We excluded deliveries with diagnostic and/or procedure codes related to a molar pregnancy, spontaneous abortion or termination, and ectopic pregnancy.
Exposure. We defined TNFi exposure based on ≥1 filled prescription for adalimumab, certolizumab, etanercept, golimumab, infliximab, and/or ≥1 infusion procedure claim for golimumab and/or infliximab during the preconception and/or gestational periods. We identified the date of the last menstrual period (i.e., onset of gestational period) based on the delivery date after applying a validated algorithm to term and preterm deliveries separately (13) . We further categorized TNFi exposure according to the timing of the filled prescription or the infusion procedure date in relation to the gestational period.
The main exposure categories were as follows: 1) RA offspring with TNFi exposure at any time during pregnancy (i.e., any prescription filled or infusion procedure claim during the gestational period), 2) RA offspring with TNFi exposure in the last 12 weeks of pregnancy (i.e., any prescription filled or infusion procedure claim within 12 weeks of delivery), 3) RA offspring with TNFi in the preconception period only (i.e., at least 1 prescription filled or infusion procedure claim in the 12 weeks preceding the gestational period, but none within the gestational period), 4) RA offspring without TNFi exposure (i.e., no prescription filled or infusion procedure claim within the gestational period and the 12 weeks preceding it), and 5) children born to non-RA mothers without TNFi exposure (i.e., no prescription filled or infusion procedure claim within the preconception and gestational periods).
Outcome measure. The outcome of interest was serious infection occurring in the offspring. We ascertained serious infections in the offspring based on ≥1 hospitalization with infection within the first 12 months of life, with a relevant diagnostic code, as primary reason for admission (i.e., hospitalization where the primary diagnosis was an infection, including ICD-9/10 coding by organism and/or organ involvement). This approach of identifying serious infections has been shown to have a high sensitivity (80%) and specificity (84%) when using chart review as a reference (14) . We only considered the first event if >1 event was identified. 1566 VINET ET AL Assessment of covariates. We assessed the following maternal comorbidity and pregnancy complications based on at least 1 physician billing and/or hospitalization with relevant diagnostic codes: pregestational diabetes mellitus, gestational diabetes mellitus, and preterm birth. We also identified in utero drug exposures to systemic corticosteroids, nonbiologic diseasemodifying antirheumatic drugs (DMARDs) (i.e., hydroxychloroquine, sulfasalazine, methotrexate, and leflunomide), and biologic DMARDs other than TNFi (i.e., rituximab, abatacept, and tocilizumab), based on at least 1 prescription filled and/or perfusion procedure claim by the mother during the gestational period.
Statistical analysis. We used descriptive statistics to characterize the different exposure groups and calculated crude measures of risk (i.e., proportions and incidence rates) with 95% confidence intervals (95% CIs). As mean follow-up time for offspring was very similar across exposure groups (ranging from 285 to 296 days), we performed univariable and multivariable analyses using a generalized estimating equation (GEE) method to estimate the odds ratio (OR) for the outcome of interest (i.e., serious infections), for children born to women with RA with different TNFi exposures, relative to RA offspring unexposed to TNFi, as well as to unexposed children from unaffected mothers. The GEE method accounts for correlation between observations, which might arise from including >1 offspring from the same mother. In addition, we assessed the robustness of our effect estimates by conducting exploratory univariable and multivariable Cox proportional hazards analyses, which provided very similar results. In our multivariable analyses, we adjusted for maternal age, pregestational diabetes mellitus, gestational diabetes mellitus, preterm birth, and medications (i.e., corticosteroids and nonbiologic and biologic DMARDs). All analyses were performed using SAS, version 9.4.
Patient involvement. Patient advocates from the Canadian Arthritis Patient Alliance (CAPA) were involved in setting the research question, developing the study protocol, and interpreting the study findings. We plan to disseminate the results of the research to relevant patient communities (e.g., CAPA, the Arthritis Society, the Arthritis Foundation, CreakyJoints, and the ArthritisPower patient registry).
RESULTS
We identified 2,989 RA offspring and 14,596 matched offspring unexposed to maternal RA (see the patient selection flow chart, Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40536/abstract). Among RA offspring, 380 (12.7%) were exposed to TNFi during pregnancy, 133 (4.4%) were unexposed during pregnancy but exposed in the preconception period, and 2,476 (82.8%) were unexposed during both the pregnancy and preconception periods. Mean maternal age was similar across all RA groups and non-RA mothers (Table 1) .
Among mothers with RA a higher proportion had pregestational diabetes mellitus and a higher proportion experienced pregnancy complications, such as preterm births and gestational diabetes mellitus (Table 1 ), compared to unaffected mothers. In addition, in utero drug exposures to corticosteroids and nonbiologic DMARDs were more frequent in RA offspring compared to offspring of non-RA mothers.
Over the first year of life, the percentage of serious infections in RA offspring with no TNFi exposure (2.0%; 95% CI 1.5, 2.6) was almost identical to that in non-RA offspring (1.9%; 95% CI 1.7, 2.2), while the percentage of serious infections in RA offspring with TNFi exposure was 3.2% (95% CI 1.5, 5.6). With regard to TNFi exposure in the third trimester, the percentage of serious infections was 3.2% (95% CI 1.2, 7.7), while for TNFi exposure in the preconception period only, it was 1.5% (95% CI 0.3, 5.9) ( Table 2) .
In multivariable analyses, we did not find an increased risk of serious infections in RA offspring (Table 3 and Figure 1) . The OR estimates for serious infections in RA offspring exposed to TNFi during pregnancy versus unexposed RA offspring were fairly wide and precluded a definitive conclusion (OR 1.4, 95% CI 0.7, 2.8), as were the results when we restricted TNFi exposure to the third trimester versus unexposed RA offspring (OR 1.4, 95% CI 0.5, 3.6).
When we looked at the percentage of serious infections in RA offspring exposed to specific TNFi (Table 4) , we observed a trend toward more serious infections in RA offspring exposed to infliximab as opposed to those exposed to other TNFi (absolute risk difference 5.4%; 95% CI À1.1, 20.4). However, the 95% CIs for all the estimates were overlapping and, particularly in the case of golimumab and certolizumab, very imprecise.
We evaluated the risk of serious infections in RA offspring exposed to infliximab as opposed to other TNFi in an exploratory multivariable analysis, adjusting for maternal age and in utero corticosteroid exposure (but unable to control for preterm birth and gestational diabetes mellitus since no case occurred for these covariates). Again, there was a trend for an increased risk of serious infections in RA offspring exposed to infliximab during pregnancy versus RA offspring exposed to other TNFi, although the 95% CI included the possibility of no difference (OR 3.0, 95% CI 0.7, 11.8).
The most frequent type of serious infections in RA offspring exposed to TNFi, unexposed RA offspring, and non-RA offspring was acute bronchiolitis due to respiratory syncytial virus, accounting for 36% (95% CI 14, 64), 31% (95% CI 19, 46), and 33% (95% CI 27, 38) of cases, respectively, in these 3 groups (Table 5) . Among all cases of serious infection occurring in RA offspring (exposed and unexposed to TNFi), we did not identify any case of TB.
DISCUSSION
Within the largest cohort of RA offspring exposed to TNFi ever assembled, we did not detect a marked excess risk associated with overall TNFi exposure during the preconception and gestational period. In addition, we did not identify any cases of TB.
We observed a trend in the risk of serious infections in RA offspring exposed to infliximab, as opposed to other TNFi, during pregnancy. In a recent study of 80 pregnant women with inflammatory bowel disease (IBD) exposed to adalimumab or infliximab, investigators assessed maternal and cord blood levels of TNFi (15) . The median ratio of infant-to-mother drug concentration at birth was 1.21 for adalimumab (95% CI 0.94, 1.49) and 1.97 for infliximab (95% CI 1.50, 2.43). The investigators showed that the mean half-life of infliximab and adalimumab was, respectively, 3.7 and 2.0 times longer in infants than in adult nonpregnant patients. This translated to a longer mean time to drug clearance in infants exposed in utero to infliximab as opposed to those exposed to adalimumab (respectively, 7.3 months [95% CI 6.2, 8.3] and 4.0 months [95% CI 2.9, 5.0]) (15) . Of note, drug concentrations were detectable up to 12 months of age in offspring exposed to infliximab. These data suggest that the pharmacokinetic properties of TNFi (i.e., their half-life) combined with their * PAROUS = Pregnancies in RA Mothers and Outcomes in Offspring in the United States; 95% CI = 95% confidence interval; RA = rheumatoid arthritis; TNFi = tumor necrosis factor inhibitors. immunologic structure (i.e., harboring an Fc fragment or not) influence drug levels in exposed offspring and the potential risk of having a serious infection. Our study has many strengths. It is the first study to evaluate the risk of serious infections in RA offspring exposed to TNFi, using an RA group and general population unexposed group as comparators. Owing to the availability of data on maternal medical diagnoses and prescription claims preceding delivery, we were able to account for important confounding factors, such as other medications, and present adjusted effect estimates for each comparison. Another strength of our study resides in the use of a large health plan database, which allowed us to assess a rare outcome in RA offspring exposed to TNFi. In addition, we used case definitions for RA and serious infections that have been shown to be valid in prior studies (12, 14) . Moreover, our data source (i.e., MarketScan) has been extensively used for the conduct of pharmacoepidemiologic studies in rheumatic diseases, particularly related to biologic DMARDs (such as TNFi) and RA outcomes (16) (17) (18) (19) . Furthermore, administrative database studies like ours are less prone to selection bias or recall bias compared to drug or pregnancy registries, which might differentially select drug-exposed subjects based on certain characteristics and/or outcomes or collect exposure information after the outcome has occurred (20) . We must acknowledge some potential limitations, particularly TNFi exposure misclassification. Exposure to TNFi was defined based on filled prescriptions, except for infliximab and golimumab exposures, which were also identified by infusion procedure codes. There might be some concerns that filled prescriptions may not have reflected actual use. However, it is likely that most women who filled a prescription for TNFi took at least 1 dose, because within the MarketScan commercial database the vast majority of subjects have out-of-pocket costs associated with prescriptions filled (21) . Thus, we believe this would not have invalidated our findings.
As MarketScan (like most administrative databases) does not provide information on the gestational age at birth and/or the last menstrual period, we estimated the gestational period by applying a validated algorithm to term and preterm deliveries separately (13) . Thus, misclassification of TNFi during the gestational period is possible. However, since our sensitivity analysis restricted to RA offspring exposed to TNFi in the 12 weeks prior to delivery showed a similar effect estimate to the one obtained in our primary analysis, we do not think that misclassification explains all of our study findings.
Since MarketScan does not explicitly record RA activity measures, our study might be subject to residual confounding by this factor. However, we adjusted for important drug exposures, such as the use of steroids and nonbiologic DMARDs, which might be associated with high disease activity. Thus, by accounting for medication exposures, this might have at least partially controlled for disease activity.
To date, there have been limited data on the risk of serious infections in children born to mothers with inflammatory conditions such as IBD and exposed in utero to TNFi. Mahadevan et al have reported findings from the Pregnancy in Inflammatory Bowel Diseases And Neonatal Outcomes (PIANO) registry, a US prospective cohort of pregnant women with IBD and their offspring followed up until 12 months after delivery (22) . PIANO includes 102 offspring exposed to TNFi monotherapy, 59 offspring exposed to combination therapy with TNFi and thiopurines, as well as an unexposed group of 265 children. The authors reported an increased risk of infections at 12 months of age in offspring exposed to combination therapy with TNFi and thiopurines relative to the unexposed group (relative risk [RR] 1.50, 95% CI 1.08, 2.09). However, they did not report a specific effect estimate for the risk of infections in children exposed to TNFi monotherapy (compared to unexposed offspring). In addition, the study results have only been reported in abstract form so far.
In the study mentioned above that evaluated 80 IBD offspring exposed in utero to adalimumab or infliximab, Julsgaard et al assessed the risk of infections in the first year of life, as reported by the mothers (15) . The investigators did not observe an increased risk of infections in children exposed to TNFi monotherapy after the thirtieth gestational week compared to those who were only exposed before the thirtieth gestational week (RR 0.54, 95% CI 0.26, 1.16). However, offspring exposed to both TNFi and thiopurines had a ≥2-fold increase in the risk of infections compared to those only exposed to TNFi (RR 2.7, 95% CI 1.09, 6.78). These study findings and the preliminary results from the PIANO registry suggest that TNFi are associated with a potential increase in the risk of infections in IBD offspring when used in combination with thiopurines during pregnancy.
In summary, we did not observe a marked excess risk for serious infections in RA offspring exposed to TNFi during pregnancy, including the third trimester, versus unexposed RA offspring and children from the general population. However, we cannot exclude a differential risk according to specific TNFi, with infliximab potentially resulting in a 3-fold increase in the risk of serious infections compared to other TNFi. More studies are needed to further evaluate whether the risk of serious infections in exposed offspring is influenced by individual TNFi characteristics.
